Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCX Perioperative Chemotherapy for Gastric and Esophageal Adenocarcinoma
NCT00865982Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Sep 2008
- Primary completion
- Sep 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, cisplatin, capecitabine in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Charité – Universitätsmedizin Berlin. Status: unknown.
02
Drugs
docetaxelcisplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT00865982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00865982.